Literature DB >> 30673802

The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes.

Ming-Feng Xia1,2, Huan-Dong Lin1,2, Ling-Yan Chen3, Li Wu1,2, Hui Ma3, Qian Li1,2, Qiqige Aleteng1,2, Yu Hu3, Wan-Yuan He4, Jian Gao5,6, Hua Bian1,2, Xiao-Ying Li1,2, Xin Gao7,8.   

Abstract

AIMS/HYPOTHESIS: The rs738409 C>G variant of the patatin-like phospholipase domain containing 3 gene (PNPLA3) increases the risk of non-alcoholic fatty liver disease (NAFLD) with no predisposition for insulin resistance. In this study, we aimed to investigate the influence of PNPLA3 polymorphisms on liver fat content (LFC) and glucose metabolic variables, and the associations between these, during the natural course of body weight changes in a Chinese adult cohort.
METHODS: The LFC, measured using a quantitative ultrasound method, was prospectively monitored in 2189 middle-aged and elderly adults from the Shanghai Changfeng Study, together with changes in body weight and metabolic variables. General linear models were used to detect interactive effects between the PNPLA3 rs738409 genotype and 4 year changes in body weight on liver steatosis and glucose metabolism.
RESULTS: The PNPLA3 homozygous GG genotype dissociated the changes in the LFC and OGTT 2 h post-load blood glucose (PBG) in relation to 4 year changes in body weight. PNPLA3 GG genotype carriers showed greater increases in the LFC and serum alanine aminotransferase (ALT) but lower PBG elevation and incident diabetes than PNPLA3 wild-type (CC) genotype carriers exhibiting the same degree of body weight increase. The interactions between the PNPLA3 genotype and changes in body weight on the LFC (false discovery rate [FDR]-adjusted pinteraction = 0.044) and ALT (FDR-adjusted pinteraction = 0.044) were significant. Subgroup analyses showed that the effect of the PNPLA3 GG genotype on changes in the LFC and PBG was only observed in metabolically unhealthy participants with insulin resistance or abdominal obesity. CONCLUSIONS/
INTERPRETATION: The PNPLA3 GG genotype interacted with changes in body weight to aggravate liver steatosis but reduced the risk of incident type 2 diabetes in metabolically unhealthy participants.

Entities:  

Keywords:  Body weight; Diabetes; Gene–environment interaction; NAFLD; PNPLA3 gene variant

Mesh:

Substances:

Year:  2019        PMID: 30673802     DOI: 10.1007/s00125-018-4805-x

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  39 in total

1.  Intensive lifestyle treatment for non-alcoholic fatty liver disease in children with severe obesity: inpatient versus ambulatory treatment.

Authors:  B G P Koot; O H van der Baan-Slootweg; S Vinke; A E Bohte; C L J Tamminga-Smeulders; P L M Jansen; J Stoker; M A Benninga
Journal:  Int J Obes (Lond)       Date:  2015-08-28       Impact factor: 5.095

2.  The PNPLA3 SNP rs738409:G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohort.

Authors:  Peter J Meffert; Katja D Repp; Henry Völzke; F Ulrich Weiss; Georg Homuth; Jens P Kühn; Markus M Lerch; Ali A Aghdassi
Journal:  J Hepatol       Date:  2017-12-11       Impact factor: 25.083

3.  I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.

Authors:  Jin-Ho Park; BeLong Cho; Hyuktae Kwon; Daria Prilutsky; Jae Moon Yun; Ho Chun Choi; Kyu-Baek Hwang; In-Hee Lee; Jong-Il Kim; Sek Won Kong
Journal:  Liver Int       Date:  2015-07-23       Impact factor: 5.828

Review 4.  5. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2018.

Authors: 
Journal:  Diabetes Care       Date:  2018-01       Impact factor: 19.112

Review 5.  The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2.

Authors:  Quentin M Anstee; Christopher P Day
Journal:  Semin Liver Dis       Date:  2015-09-17       Impact factor: 6.115

6.  Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.

Authors:  Panu K Luukkonen; You Zhou; Sanja Sädevirta; Marja Leivonen; Johanna Arola; Matej Orešič; Tuulia Hyötyläinen; Hannele Yki-Järvinen
Journal:  J Hepatol       Date:  2016-01-11       Impact factor: 25.083

7.  PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.

Authors:  Marcin Krawczyk; Raúl Jiménez-Agüero; José M Alustiza; José I Emparanza; María J Perugorria; Luis Bujanda; Frank Lammert; Jesús M Banales
Journal:  Surg Obes Relat Dis       Date:  2016-07-01       Impact factor: 4.734

8.  Polymorphisms in the adiponutrin gene are associated with increased insulin secretion and obesity.

Authors:  Lovisa E Johansson; Ulf Lindblad; Charlotte A Larsson; Lennart Råstam; Martin Ridderstråle
Journal:  Eur J Endocrinol       Date:  2008-08-26       Impact factor: 6.664

9.  Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method.

Authors:  Ming-Feng Xia; Hong-Mei Yan; Wan-Yuan He; Xiao-Ming Li; Chao-Lun Li; Xiu-Zhong Yao; Ruo-Kun Li; Meng-Su Zeng; Xin Gao
Journal:  Obesity (Silver Spring)       Date:  2011-10-20       Impact factor: 5.002

10.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.

Authors:  Stefano Romeo; Julia Kozlitina; Chao Xing; Alexander Pertsemlidis; David Cox; Len A Pennacchio; Eric Boerwinkle; Jonathan C Cohen; Helen H Hobbs
Journal:  Nat Genet       Date:  2008-09-25       Impact factor: 38.330

View more
  8 in total

Review 1.  Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation.

Authors:  Benedict J Maliakkal
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

Review 2.  NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment.

Authors:  Ming-Feng Xia; Hua Bian; Xin Gao
Journal:  Front Pharmacol       Date:  2019-08-06       Impact factor: 5.810

Review 3.  Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk.

Authors:  Siarhei A Dabravolski; Evgeny E Bezsonov; Mirza S Baig; Tatyana V Popkova; Ludmila V Nedosugova; Antonina V Starodubova; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

4.  Association of rs738409 Polymorphism in Adiponutrin Gene with Liver Steatosis and Atherosclerosis Risk Factors in Greek Children and Adolescents.

Authors:  Eleanna Stasinou; Elpida Emmanouilidou-Fotoulaki; Maria Kavga; Fotini Sotiriadou; Alexandros F Lambropoulos; Maria Fotoulaki; Kyriaki Papadopoulou-Legbelou
Journal:  Nutrients       Date:  2022-08-23       Impact factor: 6.706

Review 5.  Update on Non-Alcoholic Fatty Liver Disease-Associated Single Nucleotide Polymorphisms and Their Involvement in Liver Steatosis, Inflammation, and Fibrosis: A Narrative Review

Authors:  Fajar Dwi Astarini; Neneng Ratnasari; Widya Wasityastuti
Journal:  Iran Biomed J       Date:  2022-07-01

Review 6.  Research progress, challenges and perspectives on PNPLA3 and its variants in Liver Diseases.

Authors:  Hongjiao Xiang; Zecheng Wu; Junmin Wang; Tao Wu
Journal:  J Cancer       Date:  2021-08-13       Impact factor: 4.207

7.  Type 2 Diabetes, PNPLA3 rs738409 Polymorphism, and the Risk of Liver Cirrhosis: Analysis of Taiwan Biobank.

Authors:  Kuan-Chun Hsueh; Oswald Ndi Nfor; Shu-Yi Hsu; Shun-Fa Yang; Yung-Po Liaw
Journal:  Front Genet       Date:  2022-03-07       Impact factor: 4.599

8.  Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Nader Salari; Niloufar Darvishi; Kamran Mansouri; Hooman Ghasemi; Melika Hosseinian-Far; Fateme Darvishi; Masoud Mohammadi
Journal:  BMC Endocr Disord       Date:  2021-06-19       Impact factor: 2.763

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.